Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Vivmark Residential Common Shares of Beneficial Interest trades at $60.73 (market cap $47.36B). The key difference: Vivmark Residential Common Shares of Beneficial Interest is far larger — about 9.7× Travere Therapeutics Inc. Common Stock's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays a 4.59% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Vivmark Residential Common Shares of Beneficial Interest for 6 Days on average.
| TVTX | VMRK | |
|---|---|---|
Market Cap | $4.88B | $47.36B |
Volume | 1,668,577 | 4,011,655 |
Sector | Health | Real Estate |
52-Week High | $67.52 | $70.15 |
52-Week Low | $26.79 | $57.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $5.01B | $56.46B |
Dividend Yield | — | 4.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
VMRK trades at $61.2, down 0.08% on the day, with a bearish technical signal and neutral oscillators. The company reported revenue of $3.04B and net income of $1.05B for 2025, but recent quarterly EPS misses and a slight decline in 2026 profit margins highlight near-term challenges. Recent news includes institutional buying and a credit rating upgrade to 'A' by S&P Global Ratings on August 18, 2026.
The outlook is mixed: analyst consensus is a buy with a $71.67 price target, but technical weakness and earnings misses pose risks. Opportunities include strong profitability and institutional support, while risks involve execution post-merger and market volatility. The stock's valuation metrics suggest it is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Vivmark Residential Common Shares of Beneficial Interest
Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.
Read more on VMRK →
